Back to Search Start Over

Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib

Authors :
Thorsten Hornung
Thomas Bieber
Viktor Janzen
Franz-Josef Heidgen
Dominik Wolf
Joerg Wenzel
Source :
New England Journal of Medicine. 371:2537-2538
Publication Year :
2014
Publisher :
Massachusetts Medical Society, 2014.

Abstract

Myelofibrosis, with positivity for the JAK2 V617F mutation, developed in a patient with long-standing, poorly controlled dermatomyositis. When the myelofibrosis was treated with ruxolitinib, the dermatomyositis went into remission.

Subjects

Subjects :
Ruxolitinib
medicine.medical_specialty
business.industry
General Medicine
Dermatomyositis
medicine.disease
Dermatology
hemic and lymphatic diseases
Mutation (genetic algorithm)
medicine
Myelofibrosis
business
JAK2 V617F
medicine.drug

Details

ISSN :
15334406 and 00284793
Volume :
371
Database :
OpenAIRE
Journal :
New England Journal of Medicine
Accession number :
edsair.doi...........dc70c44729e35a645407863fe7437d33
Full Text :
https://doi.org/10.1056/nejmc1412997
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details